Literature DB >> 10511398

Pharmacokinetics of antibiotics in burn patients.

M J Weinbren1.   

Abstract

Drug pharmacokinetics are significantly altered in the burned patient but the interplay of a large number of variables is involved in deciding how an individual will deal with a drug. Consequently the burn patient population shows significant inter- and intrapatient variation. In 1976 altered aminoglycoside pharmacokinetics and the need for increased dosage in burn patients was reported but, despite this early study, a review of the currently available literature shows that for many drugs there is a paucity of information to support current dosage recommendations. In addition, many reports are based upon small numbers of patients, and even in larger studies there is no standardization of the study population with regard to the important variables known to affect drug handling. For the sub-population of burn patients who eliminate drugs extremely rapidly, a concern exists over the adequacy of antibiotic dosing. It is suggested that antibiotic serum concentrations be measured for all drugs in every patient to ascertain whether there is a significant problem with dosing. Additionally, future pharmacokinetic studies need to be standardized in burn patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511398     DOI: 10.1093/jac/44.3.319

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  28 in total

1.  Population pharmacokinetics of ceftazidime in burn patients.

Authors:  Eric Dailly; Michel Pannier; Pascale Jolliet; Michel Bourin
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

2.  Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.

Authors:  Tyree H Kiser; Dorie W Hoody; Marilee D Obritsch; Colleen O Wegzyn; Paulus C Bauling; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Population pharmacokinetics of arbekacin in burn patients.

Authors:  Jong Hyun Kim; Hyon-Oh Lah; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 2.953

4.  Population pharmacokinetic analysis of piperacillin in burn patients.

Authors:  Sangil Jeon; Seunghoon Han; Jongtae Lee; Taegon Hong; Jeongki Paek; Heungjeong Woo; Dong-Seok Yim
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

5.  After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients.

Authors:  Katharina Olbrisch; Tobias Kisch; Julia Thern; Evelyn Kramme; Jan Rupp; Tobias Graf; Sebastian G Wicha; Peter Mailänder; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-27       Impact factor: 3.000

Review 6.  Diabetes mellitus and burns. Part I-basic science and implications for management.

Authors:  Ioannis Goutos; Rebecca Spenser Nicholas; Atisha A Pandya; Sudip J Ghosh
Journal:  Int J Burns Trauma       Date:  2015-03-20

7.  Population pharmacokinetic analysis of colistin in burn patients.

Authors:  Jongtae Lee; Seunghoon Han; Sangil Jeon; Taegon Hong; Wonkeun Song; Heungjeong Woo; Dong-Seok Yim
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

8.  Tissue accumulation of cephalothin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalothin concentrations in burn patients and healthy volunteers.

Authors:  Andrew J Dalley; Jeffrey Lipman; Renae Deans; Bala Venkatesh; Michael Rudd; Michael S Roberts; Sheree E Cross
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients.

Authors:  Silvia Regina Cavani Jorge Santos; Edvaldo Vieira Campos; Cristina Sanches; David Souza Gomez; Marcus Castro Ferreira
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

10.  Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.

Authors:  A García-de-Lorenzo; S Luque; S Grau; A Agrifoglio; L Cachafeiro; E Herrero; M J Asensio; S M Sánchez; J A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.